Foghorn Therapeutics Inc. (FHTX)
FHTX Stock Price Chart
Explore Foghorn Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze FHTX price movements and trends.
FHTX Company Profile
Discover essential business fundamentals and corporate details for Foghorn Therapeutics Inc. (FHTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
23 Oct 2020
Employees
112.00
Website
https://foghorntx.comCEO
Adrian H. B. Gottschalk
Description
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
FHTX Financial Timeline
Browse a chronological timeline of Foghorn Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 3 Nov 2025
EPS estimate is -$0.27, while revenue estimate is $5.86M.
Earnings released on 5 Aug 2025
EPS came in at -$0.28 surpassing the estimated -$0.31 by +9.68%, while revenue for the quarter reached $7.56M , missing expectations by -7.54%.
Earnings released on 14 May 2025
EPS came in at -$0.30 matching the estimated -$0.30, while revenue for the quarter reached $5.95M , missing expectations by -4.61%.
Earnings released on 6 Mar 2025
EPS came in at -$0.30 surpassing the estimated -$0.43 by +30.23%, while revenue for the quarter reached $2.86M , missing expectations by -67.06%.
Earnings released on 4 Nov 2024
EPS came in at -$0.31 surpassing the estimated -$0.42 by +26.19%, while revenue for the quarter reached $7.81M , missing expectations by -4.03%.
Earnings released on 8 Aug 2024
EPS came in at -$0.45 surpassing the estimated -$0.60 by +25.00%, while revenue for the quarter reached $6.89M , beating expectations by +14.04%.
Earnings released on 6 May 2024
EPS came in at -$0.59 falling short of the estimated -$0.55 by -7.27%, while revenue for the quarter reached $5.05M , missing expectations by -26.92%.
Earnings released on 7 Mar 2024
EPS came in at -$0.57 surpassing the estimated -$0.79 by +27.85%, while revenue for the quarter reached $5.77M , beating expectations by +24.87%.
Earnings released on 2 Nov 2023
EPS came in at -$0.34 surpassing the estimated -$0.72 by +52.78%, while revenue for the quarter reached $17.48M , beating expectations by +278.31%.
Earnings released on 4 Aug 2023
EPS came in at -$0.70 surpassing the estimated -$0.73 by +4.11%, while revenue for the quarter reached $5.60M , missing expectations by -10.56%.
Earnings released on 8 May 2023
EPS came in at -$0.73 falling short of the estimated -$0.68 by -7.35%, while revenue for the quarter reached $5.31M , missing expectations by -15.19%.
Earnings released on 9 Mar 2023
EPS came in at -$0.69 falling short of the estimated -$0.59 by -16.95%, while revenue for the quarter reached $4.18M , missing expectations by -16.98%.
Earnings released on 8 Nov 2022
EPS came in at -$0.62 falling short of the estimated -$0.60 by -3.33%, while revenue for the quarter reached $6.63M , missing expectations by -21.77%.
Earnings released on 9 Aug 2022
EPS came in at -$0.66 falling short of the estimated -$0.53 by -24.53%, while revenue for the quarter reached $4.49M , missing expectations by -53.15%.
Earnings released on 9 May 2022
EPS came in at -$0.65 falling short of the estimated -$0.40 by -62.50%, while revenue for the quarter reached $3.92M , missing expectations by -58.43%.
Earnings released on 10 Mar 2022
EPS came in at -$0.77 falling short of the estimated -$0.74 by -4.05%, while revenue for the quarter reached $713.00K , beating expectations by +0.46%.
Earnings released on 9 Nov 2021
EPS came in at -$0.71 falling short of the estimated -$0.66 by -7.58%, while revenue for the quarter reached $41.00K , missing expectations by -83.60%.
Earnings released on 10 Aug 2021
EPS came in at -$0.63 matching the estimated -$0.63, while revenue for the quarter reached $279.00K , meeting expectations.
Earnings released on 11 May 2021
EPS came in at -$0.62 surpassing the estimated -$0.63 by +1.59%, while revenue for the quarter reached $286.00K , missing expectations by -1.56%.
Earnings released on 18 Mar 2021
EPS came in at -$1.86 falling short of the estimated -$0.45 by -313.33%, while revenue for the quarter reached $251.00K .
Earnings released on 4 Dec 2020
EPS came in at -$3.12 falling short of the estimated -$1.72 by -81.40%, while revenue for the quarter reached $179.00K .
Earnings released on 23 Oct 2020
EPS came in at -$0.71 .
FHTX Stock Performance
Access detailed FHTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.